Witney Frank 4

What Happened
Witney Frank, a director of Alamar Biosciences, reported a series of "other" derivative transactions on 2026-04-20 that show matched dispositions and acquisitions totaling 206,781 shares (49,627; 33,085; 124,069). All transactions are reported at $0.00 and are coded as derivative "other acquisition or disposition (J)," indicating reclassification/conversion activity rather than open-market buys or sales. No cash changed hands in these entries.

Key Details

• Transaction date: 2026-04-20; all reported at $0.00 (derivative transactions, code J).
• Individual entries: disposed and reacquired 49,627; 33,085; and 124,069 shares (pairs of equal disposed/acquired amounts).
• Total affected shares: 206,781.
• Shares owned after transaction: not disclosed in the supplied filing details.
• Footnotes: F1 notes Class B Common was reclassified into Common immediately prior to the issuer's IPO; F2 indicates some shares are fully vested; F3 and F4 describe option vesting schedules (monthly over 48 months and a 25% cliff then monthly vesting, respectively).
• Filing timeliness: reported on the same date (2026-04-20) — appears timely.

Context
These entries look administrative (conversion/reclassification of derivative interests—e.g., Class B to Common stock around an IPO) rather than purchases or sales that signal a trading view. For retail investors, note this is not an open-market purchase or cash sale; some related holdings are subject to vesting schedules per the footnotes, while others are fully vested.